During the past decade, Accelovance conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Accelovance" #1 sponsor was "Inovio Pharmaceuticals" with 2 trials, followed by "Fraunhofer, Center for Molecular Biotechnology" with 1 trials sponsored, "Medicago" with 1 trials sponsored, "Ology Bioservices" with 1 trials sponsored and "VeraLight, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

According to Clinical.Site data, the most researched conditions in "Accelovance" are "Healthy" (2 trials), "Flu" (1 trials), "Gestational Diabetes" (1 trials), "Impaired Glucose Tolerance" (1 trials) and "Influenza" (1 trials). Many other conditions were trialed in "Accelovance" in a lesser frequency.

Most popular intervention types in "Accelovance" are "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Dose given at Day 0" (1 trials), "INO-3401 + EP" (1 trials), "Pfs25 VLP- FhCMB" (1 trials), "Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine" (1 trials) and "VGX-3400X" (1 trials). Other intervention names were less common.

The vast majority of trials in "Accelovance" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Accelovance". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Accelovance, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Accelovance, 5 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".